Citations

Clear

7 citation(s) found for "Kirby, Brian".

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II
Tzellos, Thrasyvoulos , Giamarellos‐Bourboulis, Evangelos J., Straalen, Kelsey R. van, Martorell, Antonio, Kirby, Brian, Alavi, Afsaneh, Khattri, Saakshi , Gulliver, Wayne, Sayed, Christopher J., Davis, Leah , Rolleri, Robert, Crater, Christina , Pansar, Ingrid, Zouboulis, CC, Giamarellos‐Bourboulis, Evangelos J. , Straalen, Kelsey R. van , Martorell, Antonio , Kirby, Brian , Alavi, Afsáneh , Hayama, Koremasa , Sayed, Christopher J. , Pansar, Ingrid, Lambert, Jérémy

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | February 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70356 | PMID 41689425 Get It

Abstract Background Hidradenitis suppurativa (HS) is a chronic, relapsing, debilitating skin disease characterized by deep‐seated nodules, abscesses and tunnels. Objectives To investigate the efficacy of bimekizumab using International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in patients with moderate to severe HS in the pooled BE HEARD I and II Phase 3 studies. Methods Patients received (initial/maintenance) bimekizumab 320 mg every 2 weeks (Q2W)/Q2W, bimekizumab Q2W/every 4 weeks (Q4W), bimekizumab Q4W/Q4W or placebo/bimekizumab Q2W. Change from baseline (CfB) in IHS4, IHS4 severity stages and the dichotomous IHS4‐55/75/90/100 (an improvement of at least 55%/75%/90%/100% in IHS4 from baseline) are reported to Week 48. Lesion count data by lesion type are reported to Week48. Results In total, 1014 patients were enrolled across BE HEARD I and II. At baseline, mean (standard deviation [SD]) IHS4 for bimekizumab‐treated patients ranged from 33.4 (25.4) for bimekizumab Q2W/Q2W to 36.0 (34.0) for bimekizumab Q2W/Q4W versus 30.6 (21.8) for placebo. At Week16, patients receiving bimekizumab demonstrated greater reductions in mean (SD) IHS4 from baseline, ranging from −17.2 (24.8) for bimekizumab Q4W/Q4W to −17.8 (21.1) for bimekizumab Q2W/Q2W versus −6.1 (16.3) for placebo. Proportions of patients with severe HS at baseline ranged from 83.7% (bimekizumab Q2W/Q2W) to 88.4% (bimekizumab Q2W/Q4W) and decreased by ~50% to Week48 across all treatment arms, ranging from 28.6% (placebo/bimekizumab Q2W) to 34.3% (bimekizumab Q2W/Q2W). Proportions of patients with IHS4 = 0 at Week48 ranged from 23.7% (bimekizumab Q2W/Q4W) to 26.7% (placebo/bimekizumab Q2W). At Week16, IHS4‐55, IHS4‐75, IHS4‐90 and IHS4‐100 thresholds were achieved by greater proportions of patients treated with bimekizumab versus placebo, while comparable improvements were seen across treatment arms from Week16 to Week48. At Week16, lesion counts were lower for patients treated with bimekizumab versus placebo, decreasing to comparable numbers across all groups at Week48. Conclusions Bimekizumab‐treated patients showed improvements across IHS4 outcome measures.
Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Soussain, Carole , Lewis, Katharine L. , Fox, Judith, Ward, Renee, Peterson, Caryn, Cravets, Matt , Mathias, Anita, Sosa, Judith, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark J., Steinberg, Marcos W, Lewis, Katharine L , Issa, Samar , Grommes, Christian , Kirby, Brian J, Tun, Han W.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12068-12069

10.1182/blood-2022-158599 Get It

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LY
Soussain, Carole , Ward, Renee, Peterson, Caryn, Cravets, Matt , Mathias, Anita, Sosa, Judith, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark J., Steinberg, Marcos W, Grommes, Christian , Issa, Samar , Kirby, Brian, Tun, Han W.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i9-i9

10.1093/noajnl/vdac078.035 Get It

Abstract BTK plays an important role in B cell receptor and Toll-like receptor signaling pathways, which are constitutively active in primary CNS lymphomas, and hence represents an excellent therapeutic target. Ibrutinib, a first-generation BTKi, was evaluated in phase 1/2 trials for R/R PCNSL, SCNSL, and PVRL, showing limited survival benefit. GB5121 is a novel, orally available, covalent BTKi with superior specificity, CNS penetration, and CNS target occupancy in preclinical testing versus other BTKis including ibrutinib. GB5121 is well-suited for evaluation in CNS lymphoma. This is a phase 1b/2 open-label study of GB5121 in adults with R/R PCNSL, isolated SCNSL or PVRL and will be conducted in three parts: phase 1b dose-escalation, expansion, and phase 2. Eligibility criteria for phase 1b dose-escalation and expansion (N≈30 for each) include age ≥18 years, ECOG≤2, R/R PCNSL, R/R SCNSL with CNS-only relapse, or R/R PVRL. Patients with newly diagnosed PCNSL who cannot tolerate standard high-dose methotrexate-based therapies are also eligible. Patients with prior allogeneic stem cell transplant are excluded. A Bayesian optimal interval design will be employed to perform dose escalation to determine the recommended phase 2 dose (RP2D). In the absence of dose-limiting toxicity (DLT), dose levels will increase sequentially according to a modified Fibonacci approach. Safety, tolerability, PK/PD, DLT, maximum tolerated dose, and preliminary therapeutic activity will be assessed to determine the optimal biological dose informing the RP2D. Phase 1b expansion will further explore therapeutic activity and characterize safety and tolerability of GB5121 at the RP2D. Phase 2 will initiate following RP2D determination. This is a single-arm, open-label study to investigate GB5121 safety and efficacy in patients with R/R PCNSL. Adverse events will be graded per CTCAE v5.0. Clinical response will be determined using International Primary CNS Lymphoma Collaborative Group criteria. Progression-free and overall survival will be evaluated. Enrollment begins May 2022 (NCT05242146).
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
Midgette, Bria, Strunk, Andrew , Akilov, Oleg E. , Ardon, Christine B. , Cohen, Arnon D. , Cohen, Steven A. , Daveluy, Steven , Delage, M. , Esmann, Solveig, Fisher, Shani , Głowaczewska, Amelia , Brant, Elena Gonzalez, Guilbault, Sandra , Hughes, Rosalind , Ingram, John R , Jemec, Gregor B. E. , Ju, Qiang , Kappe, Naomi , Kirby, Joslyn S. , Matusiak, Łukasz , Micha, Stella, Miller, Angela P., Moseng, Dagfinn, Naik, Haley B. , Nassif, Aude , Nikolakis, Georgios , Pascual, J.C. , Resnik, Barry I., Riad, Hassan, Sayed, Christopher J. , Soliman, Yssra , Szepietowski, Jacek C. , Thorlacius, Linnea , Zee, Hessel H. van der , Villumsen, Bente , Wang, Lanqi , Garg, Amit , Cohen, Steven , Daveluy, Steven , Ingram, J R , Jemec, G B E , Micheletti, Robert , Naik, Haley , Paek, So Yeon , Sayed, Christopher , Szepietowski, Jacek C , Wang, Lanqi , Garg, Amit , Thorlacius, L , Akilov, Oleg E , van der Zee, Hessel H , Alavi, Afsáneh , Bechara, Falk G. , Mármol, V. del , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Grimstad, Øystein , Hamzavi, Iltefat H. , Kirby, Brian , Lowes, Michelle A , Paek, So Yeon , Prens, Errol P. , Smith, Saxon D. , Tan, Jerry K.L. , Tzellos, Thrasyvoulos , Zouboulis, Christos C.

Mayo Clinic

British Journal of Dermatology | July 30, 2022 | Volume: 187 | Issue: 6 | Pages: 927-935

10.1111/bjd.21798 | PMID 36056741 Get It

Abstract Background Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. Methods Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients’ self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from ‘very dissatisfied’ to ‘very satisfied’. Results The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62–2·44, P < 0·001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2·36, 95% CI 1·74–3·19, P < 0·001] relative to treatment with nonbiologic systemic medications. Factors associated with lower treatment satisfaction included smoking (OR 0·78, 95% CI 0·62–0·99; active vs. never), depression (OR 0·69, 95% CI 0·54–0·87), increasing number of comorbidities (OR 0·88 per comorbidity, 95% CI 0·81–0·96) and increasing flare frequency. Conclusions There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication. Factors that appear to lower treatment satisfaction include active smoking, depression, accumulation of comorbid conditions and increasing flare frequency. Awareness of these factors may support partnered decision making with the goal of improving treatment outcomes. What is already known about this topic? Nearly half of patients with hidradenitis suppurativa report dissatisfaction with their treatments. What does this study add? Satisfaction with treatment is increased by receiving care from a dermatologist and treatment with biologics.Satisfaction with treatment is decreased by tobacco smoking, accumulation of comorbid conditions including depression, and higher flare frequency. What are the clinical implications of this work? Awareness of the identified factors associated with poor treatment satisfaction may support partnered decision making and improve treatment outcomes.
Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply
Levesque, Barrett G., Feagan, Brian G. , Jucov, Alina , Bhandari, Bal Raj, Pai, Rish K. , Meadows, Kristen Taylor, Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin , Biene, Courtney Van, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J. , Danese, Silvio , Sandborn, W J , Danese, Silvio , Kirby, Brian J. , Osterhout, Robin E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 4, 2022 | Volume: 55 | Issue: 6 | Pages: 735-736

10.1111/apt.16795 | PMID 35245951 Get It

LINKED CONTENTThis article is linked to Danese et al papers. To view these articles, visit https://doi.org/10.1111/apt.16753 and https://doi.org/10.1111/apt.16761
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis
Levesque, Barrett G., Feagan, Brian G. , Jucov, Alina , Bhandari, Bal Raj, Pai, Rish K. , Meadows, Kristen Taylor, Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin , Biene, Courtney Van, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J. , Danese, Silvio , Sandborn, W J , Danese, Silvio , Kirby, Brian J. , Osterhout, Robin E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 11, 2022 | Volume: 55 | Issue: 4 | Pages: 401-411

10.1111/apt.16753 | PMID 35014040 Get It

SummaryBackgroundEpithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut.AimsTo evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of GB004 in patients with active UC.MethodsThis double‐blind, placebo‐controlled study randomised patients 2:1 to receive an oral solution of GB004 120 mg or placebo once daily for 28 days. Eligible patients had a Robarts Histopathology Index score ≥4 with neutrophils in the epithelium, total Mayo Clinic score 3‐12, Mayo Clinic endoscopic subscore ≥1, and blood in the stool, despite treatment with 5‐aminosalicylates, corticosteroids or immunosuppressants.ResultsThirty‐four patients were randomised. GB004 120 mg for 28 days was generally well‐tolerated. Adverse events occurred in 27.3% (3/11) and 39.1% (9/23) of patients in the placebo and GB004 groups respectively. Nausea and dysgeusia were most commonly reported in the GB004 group (0% for placebo and 21.7% [5/23] and 13.0% [3/23] respectively for GB004). There were no treatment‐related serious adverse events or deaths. GB004 exhibited minimal accumulation, with higher colonic concentrations relative to plasma. Exploratory pharmacodynamic and efficacy analyses demonstrated GB004 target engagement and numerically higher proportions of patients achieving improvement in multiple measures of disease activity, respectively, at day 28 for GB004 compared to placebo.ConclusionResults from this phase 1b trial support evaluation of the full therapeutic potential of GB004 for the treatment of UC. A phase 2 study (NCT04556383) is ongoing. Clinicaltrials.gov NCT03860896.
Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis
Ryan, Caitriona , Kelleher, John F., Fagan, M. F., Collins, Paul M. , Barker, Juliet N. , Allen, Michael , Hagan, Richard , Renfro, Lindsay A. , Rogers, Simon Neave , Kirby, Brian

Mayo Clinic

Clinical and Experimental Dermatology | April 23, 2014 | Volume: 39 | Issue: 4 | Pages: 519-524

10.1111/ced.12323 | PMID 24758522 Get It